Quince Therapeutics, Inc. (Nasdaq: QNCX), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for serious underserved diseases, today announced ...
A new review was published in Volume 18 of Aging on May 30, 2026, titled "The love and hate relationship between cellular ...
The high-grade glioma market is witnessing steady growth driven by the rising incidence of aggressive brain tumors, increasing awareness, and advancements ...
Zacks Small Cap Research on MSN
BDRX: Expanding phase 3 SERENTA trial into Canada; 73 patients enrolled thus far
By David Bautz, PhD NASDAQ: BDRX READ THE FULL BDRX RESEARCH REPORT Business Update Expanding Phase 3 Serenta Trial into Canada On June 29, 2026, Biodexa Pharmaceuticals, PLC (NASDAQ: BDRX) announced ...
Despite fears of an innovation slowdown, stoked by funding cuts and FDA personnel shakeups, the agency approved 17 ...
Blackberry Babe on MSN
5 amino acid essentials every plant-forward mom needs
Raising a family while sticking to a plant-forward way of eating takes real intentionality - not just with what lands on the ...
Protein is one of the most talked-about nutrients in sport. It is also one of the easiest to oversimplify. On one side, there ...
The FDA has granted Fast Track designation to BM-3103, a novel topical mTOR inhibitor for epidermolysis bullosa simplex currently in phase 2.
An antisense therapy that targets a glycine transporter restored NMDA receptor function in mouse models related to autism and ...
Spinal degeneration remains one of the leading causes of chronic disability globally, with surgical management representing a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results